MA33092B1 - Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one - Google Patents
Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-oneInfo
- Publication number
- MA33092B1 MA33092B1 MA34136A MA34136A MA33092B1 MA 33092 B1 MA33092 B1 MA 33092B1 MA 34136 A MA34136 A MA 34136A MA 34136 A MA34136 A MA 34136A MA 33092 B1 MA33092 B1 MA 33092B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline form
- pyridin
- fluorophenyl
- dihydrogenophosphate
- methyltetrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'INVENTION CONCERNE UNE FORME CRISTALLINE DU DIHYDROGÉNOPHOSPHATE DE (R)-3-(4-(2-(2-MÉTHYLTÉTRAZOL-5-YL)-PYRIDIN-5-YL)-3-FLUOROPHÉNYL)-5-HYDROXYMÉTHYL OXAZOLIDIN-2-ONE, DES PROCÉDÉS DE PRÉPARATION DE LA FORME CRISTALLINE ET DES COMPOSITIONS CONTENANT LA FORME CRISTALLINE UTILES COMME ANTIBIOTIQUES. EN OUTRE, LES DÉRIVÉS DE LA PRÉSENTE INVENTION PEUVENT EXERCER UNE PUISSANTE ACTIVITÉ ANTIBACTÉRIENNE SUR DIVERS PATHOGÈNES HUMAINS ET ANIMAUX, NOTAMMENT SUR LES BACTÉRIES GRAM-POSITIVES TELLES QUE LES STAPHYLOCOQUES, LES ENTÉROCOQUES ET LES STREPTOCOQUES, LES MICRO-ORGANISMES ANAÉROBIES TELS QUE LES BACTÉROIDES ET LES CLOSTRIDIA, ET LES MICRO-ORGANISMES ACIDO-RÉSISTANTS TELS QUE MYCOBACTERIUM TUBERCULOSIS ET MYCOBACTERIUM AVIUM. LES COMPOSITIONS CONTENANT LA FORME CRISTALLINE PEUVENT DONC ÊTRE UTILISÉES COMME ANTIBIOTIQUES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14940209P | 2009-02-03 | 2009-02-03 | |
PCT/US2010/023122 WO2010091131A1 (fr) | 2009-02-03 | 2010-02-03 | Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33092B1 true MA33092B1 (fr) | 2012-03-01 |
Family
ID=42289775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34136A MA33092B1 (fr) | 2009-02-03 | 2010-02-03 | Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one |
Country Status (29)
Country | Link |
---|---|
US (6) | US8426389B2 (fr) |
EP (1) | EP2393808B1 (fr) |
JP (1) | JP5584705B2 (fr) |
KR (3) | KR101918678B1 (fr) |
CN (2) | CN107082790A (fr) |
AP (1) | AP2987A (fr) |
AU (1) | AU2010210627B2 (fr) |
BR (1) | BRPI1008829A2 (fr) |
CA (1) | CA2751392C (fr) |
CL (1) | CL2011001855A1 (fr) |
CO (1) | CO6620071A2 (fr) |
CR (1) | CR20110464A (fr) |
CU (1) | CU24089B1 (fr) |
DO (1) | DOP2011000251A (fr) |
EC (1) | ECSP11011285A (fr) |
ES (1) | ES2734724T3 (fr) |
IL (1) | IL214401B (fr) |
MA (1) | MA33092B1 (fr) |
MX (2) | MX2011008093A (fr) |
MY (1) | MY156354A (fr) |
NZ (3) | NZ594408A (fr) |
PE (1) | PE20120585A1 (fr) |
PH (1) | PH12014500092A1 (fr) |
RU (2) | RU2011136537A (fr) |
SG (2) | SG10201500207QA (fr) |
TN (1) | TN2011000381A1 (fr) |
UA (1) | UA114068C2 (fr) |
WO (1) | WO2010091131A1 (fr) |
ZA (2) | ZA201106412B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
CN106220621B (zh) * | 2008-10-10 | 2019-06-11 | 默沙东公司 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
NZ594408A (en) | 2009-02-03 | 2014-03-28 | Trius Therapeutics | Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
US8580767B2 (en) * | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
US8461188B2 (en) | 2011-10-20 | 2013-06-11 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
WO2015054246A1 (fr) * | 2013-10-07 | 2015-04-16 | Trius Therapeutics, Inc. | Procédés de traitement de sujets présentant une insuffisance rénale à l'aide de tédizolid |
CN105229001B (zh) * | 2014-04-18 | 2017-04-26 | 杭州普晒医药科技有限公司 | 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途 |
WO2016009401A2 (fr) * | 2014-07-18 | 2016-01-21 | Dr. Reddy's Laboratories Limited | Préparation du phosphate de tédizolid |
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
WO2016063246A1 (fr) * | 2014-10-22 | 2016-04-28 | Sun Pharmaceutical Industries Limited | Forme cristalline r de phosphate de tédizolide |
WO2016088100A1 (fr) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Procédés pour préparer un phosphate de tédizolid et ses intermédiaires |
WO2016088102A1 (fr) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Procédés pour la préparation de tedizolid et de ses intermédiaires |
WO2016088101A1 (fr) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Procédés de préparation de phosphate de tédizolide et de ses intermédiaires |
CZ306245B6 (cs) * | 2014-12-11 | 2016-10-26 | Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové | Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující |
CN104558034A (zh) * | 2015-01-21 | 2015-04-29 | 齐鲁制药有限公司 | 磷酸特地唑胺二钠盐的新晶型及其制备方法 |
CN105837634B (zh) * | 2015-01-30 | 2020-09-04 | 上海创诺制药有限公司 | 一种泰地唑胺磷酸酯结晶体及其制备方法 |
CN104592218B (zh) * | 2015-02-13 | 2015-11-04 | 江苏欧信医药化工有限公司 | 一种泰地唑胺的合成方法 |
CN106146485B (zh) * | 2015-04-01 | 2021-04-30 | 上海迪赛诺化学制药有限公司 | 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体 |
CN106146558A (zh) * | 2015-04-10 | 2016-11-23 | 博瑞生物医药(苏州)股份有限公司 | 新的噁唑烷酮类化合物及其制备方法 |
CN106317114B (zh) * | 2015-07-02 | 2018-11-20 | 南京优科制药有限公司 | 一种磷酸特地唑胺的制备方法 |
CN105085570B (zh) * | 2015-09-12 | 2017-11-28 | 山东罗欣药业集团股份有限公司 | 一种磷酸特地唑胺化合物及其制备方法 |
CN105287407B (zh) * | 2015-11-24 | 2018-09-21 | 南京正大天晴制药有限公司 | 一种注射用磷酸特地唑胺 |
CN107121503B (zh) * | 2017-03-14 | 2020-04-28 | 南京优科制药有限公司 | 一种磷酸特地唑胺及其有关物质的分析方法 |
CN108948079A (zh) * | 2017-05-17 | 2018-12-07 | 上海奥博生物医药技术有限公司 | 一种特地唑胺二铵盐及晶型与其制备方法 |
WO2019118311A1 (fr) * | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Compositions pharmaceutiques de tedizolid phosphate |
US20230219941A1 (en) | 2020-06-18 | 2023-07-13 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
CN112957332B (zh) * | 2021-02-04 | 2023-04-25 | 海南通用康力制药有限公司 | 注射用磷酸特地唑胺及其质量标准 |
CN112957333B (zh) * | 2021-02-05 | 2022-11-22 | 海南通用康力制药有限公司 | 注射用磷酸特地唑胺及其制备方法 |
CN113197874B (zh) * | 2021-04-28 | 2023-05-26 | 北京福元医药股份有限公司 | 一种磷酸特地唑胺口服固体制剂 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4340606A (en) | 1980-10-23 | 1982-07-20 | E. I. Du Pont De Nemours And Company | 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents |
FR2500450A1 (fr) | 1981-02-25 | 1982-08-27 | Delalande Sa | Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique |
US4461773A (en) | 1982-09-15 | 1984-07-24 | E. I. Dupont De Nemours And Company | P-Oxooxazolidinylbenzene compounds as antibacterial agents |
CA1320730C (fr) | 1987-10-16 | 1993-07-27 | The Du Pont Merck Pharmaceutical Company | Derives d'aminomethyloxooxazolidinylaroylbenzene, agents antibacteriens |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5144911A (en) * | 1990-11-28 | 1992-09-08 | Moore Cheri L | Component bed system for a pet |
EP0610265B1 (fr) | 1991-11-01 | 1996-12-27 | PHARMACIA & UPJOHN COMPANY | Aryl- et heteroarylphenyloxazolidinones substituees, utilisees comme agents antibacteriens |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
DE69316240T2 (de) | 1992-12-08 | 1998-05-20 | Upjohn Co | Durch eine tropon gruppe substituierte phenyloxazolidinone-derivate als antibakterielles mittel |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
JP3698724B2 (ja) | 1993-11-22 | 2005-09-21 | ファルマシア・アンド・アップジョン・カンパニー | 置換−ヒドロキシアセチルピペラジンフェニルオキサゾリジノンのエステル |
GB9702213D0 (en) | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
BR0111280A (pt) | 2000-06-05 | 2003-06-10 | Dong A Pharm Co Ltd | Novos derivados de oxazolidinona e um processo para a preparação dos mesmos |
US20020115669A1 (en) | 2000-08-31 | 2002-08-22 | Wiedeman Paul E. | Oxazolidinone chemotherapeutic agents |
YU52403A (sh) | 2000-12-26 | 2006-03-03 | Dr.Reddy's Research Foundation | Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže |
DE60212959T2 (de) | 2001-04-07 | 2007-02-15 | Astrazeneca Ab | Eine sulfonimid-gruppe enthaltende oxazolidinone als antibiotika |
US6623140B2 (en) | 2001-04-13 | 2003-09-23 | Scott R. Watterson | Illumination device having multiple light sources |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
PT1427711E (pt) | 2001-09-11 | 2005-11-30 | Astrazeneca Ab | Derivados de oxazolidinona e/ou isoxazolina como agentes antibacterianos |
JP2005519870A (ja) | 2001-10-25 | 2005-07-07 | アストラゼネカ アクチボラグ | 抗菌活性をもつアリール置換オキサゾリジノン類 |
NZ515881A (en) | 2001-12-03 | 2004-09-24 | New Zealand Dairy Board | Cheese flavour ingredient and method of its production |
AR038536A1 (es) * | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
CA2477379A1 (fr) | 2002-02-28 | 2003-09-04 | Astrazeneca Ab | Composes chimiques |
IL163688A0 (en) | 2002-02-28 | 2005-12-18 | Astrazeneca Ab | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents |
US20060116400A1 (en) | 2002-11-28 | 2006-06-01 | Astrazeneca Ab | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
EP1581524A2 (fr) | 2002-11-28 | 2005-10-05 | AstraZeneca AB | Derives d`oxazolidinones comme agents bactericides |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
TW200500360A (en) | 2003-03-01 | 2005-01-01 | Astrazeneca Ab | Hydroxymethyl compounds |
GB0306358D0 (en) | 2003-03-20 | 2003-04-23 | Astrazeneca Ab | Chemical compounds |
CA2530140C (fr) | 2003-07-02 | 2010-11-09 | Merck & Co., Inc. | Antibiotiques a base d'oxazolidinone substituee par un groupe cyclipropyl et derives |
EP1654259A1 (fr) | 2003-07-02 | 2006-05-10 | Merck & Co., Inc. | Antibiotiques de type oxazolidinones a groupe cyclopropyle substitue et derives de ceux-ci |
NZ529860A (en) | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
WO2005051933A1 (fr) | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Procede ameliore de synthese d'ester test-butylique d'acide 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylique, compose intermediaire cle de la preparation d'agents antimicrobiens a l'oxazolidinone, et composes ainsi prepares |
EP1713785A1 (fr) | 2003-12-17 | 2006-10-25 | Rib-X Pharmaceuticals, Inc. | Composes heterocycliques de biaryle halogenes et methodes de fabrication et d'utilisation |
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
JP2008500317A (ja) | 2004-05-25 | 2008-01-10 | アストラゼネカ アクチボラグ | 抗菌剤としての3−’4−{6−置換アルカノイル)ピリジン−3−イル}−3−フェニル−5−(1h−1,2,3−トリアゾール−1−イルメチル)−1,3−オキサゾリジン−2−オン |
GB0411596D0 (en) | 2004-05-25 | 2004-06-30 | Astrazeneca Ab | Chemical process |
US20080064689A1 (en) | 2004-05-25 | 2008-03-13 | Astrazeneca Ab | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
US20080021071A1 (en) | 2004-05-25 | 2008-01-24 | Astrazeneca Ab | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
JP2008500319A (ja) | 2004-05-25 | 2008-01-10 | アストラゼネカ アクチボラグ | 細菌感染症の治療のためのmao阻害剤としての3−(4−(2−ジヒドロイソオキサゾール−3−イルピリジン−5−イル)フェニル−5−トリアゾール−1−イルメチルオキサゾリジン−2−オン誘導体 |
US20100286211A1 (en) | 2004-10-08 | 2010-11-11 | Biswajit Das | Oxazolidinone derivatives as antimicrobials |
US20090018123A1 (en) | 2005-06-20 | 2009-01-15 | Milind D Sindkhedkar | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation |
WO2007138381A2 (fr) | 2005-10-14 | 2007-12-06 | Targanta Therapeutics Inc. | Oxazolidinones phosphonées et leurs utilisations pour la prévention et le traitement des infections des os et des articulations |
CA2695616C (fr) * | 2007-08-06 | 2015-11-24 | Micurx Pharmaceuticals, Inc. | Orthofluorophenyle oxazolidinones antimicrobiennes pour le traitement d'infections bacteriennes |
CN101220001A (zh) * | 2008-01-25 | 2008-07-16 | 浙江博泰化工有限公司 | 一种利奈唑酮的合成方法 |
CN106220621B (zh) | 2008-10-10 | 2019-06-11 | 默沙东公司 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
NZ594408A (en) | 2009-02-03 | 2014-03-28 | Trius Therapeutics | Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
US8580767B2 (en) | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
-
2010
- 2010-02-03 NZ NZ594408A patent/NZ594408A/en active IP Right Revival
- 2010-02-03 SG SG10201500207QA patent/SG10201500207QA/en unknown
- 2010-02-03 CN CN201710063034.9A patent/CN107082790A/zh active Pending
- 2010-02-03 ES ES10703403T patent/ES2734724T3/es active Active
- 2010-02-03 EP EP10703403.5A patent/EP2393808B1/fr active Active
- 2010-02-03 CA CA2751392A patent/CA2751392C/fr active Active
- 2010-02-03 NZ NZ712289A patent/NZ712289A/en unknown
- 2010-02-03 BR BRPI1008829A patent/BRPI1008829A2/pt not_active Application Discontinuation
- 2010-02-03 SG SG2011055456A patent/SG173497A1/en unknown
- 2010-02-03 KR KR1020177034181A patent/KR101918678B1/ko active IP Right Grant
- 2010-02-03 AP AP2011005835A patent/AP2987A/xx active
- 2010-02-03 RU RU2011136537/04A patent/RU2011136537A/ru not_active Application Discontinuation
- 2010-02-03 CN CN2010800143630A patent/CN102439006A/zh active Pending
- 2010-02-03 WO PCT/US2010/023122 patent/WO2010091131A1/fr active Application Filing
- 2010-02-03 MA MA34136A patent/MA33092B1/fr unknown
- 2010-02-03 JP JP2011549242A patent/JP5584705B2/ja active Active
- 2010-02-03 RU RU2016100418A patent/RU2655928C1/ru active
- 2010-02-03 US US12/699,864 patent/US8426389B2/en active Active
- 2010-02-03 MX MX2011008093A patent/MX2011008093A/es not_active Application Discontinuation
- 2010-02-03 AU AU2010210627A patent/AU2010210627B2/en active Active
- 2010-02-03 PE PE2011001433A patent/PE20120585A1/es active IP Right Grant
- 2010-02-03 KR KR1020117020614A patent/KR101739923B1/ko active IP Right Grant
- 2010-02-03 MY MYPI2011003576A patent/MY156354A/en unknown
- 2010-02-03 NZ NZ620458A patent/NZ620458A/en unknown
- 2010-02-03 CU CU2011000155A patent/CU24089B1/es active IP Right Grant
- 2010-02-03 KR KR1020177008992A patent/KR20170040371A/ko not_active Application Discontinuation
- 2010-02-03 UA UAA201110617A patent/UA114068C2/uk unknown
-
2011
- 2011-08-01 MX MX2020011773A patent/MX2020011773A/es unknown
- 2011-08-01 DO DO2011000251A patent/DOP2011000251A/es unknown
- 2011-08-02 CO CO11097215A patent/CO6620071A2/es not_active Application Discontinuation
- 2011-08-02 IL IL214401A patent/IL214401B/en active IP Right Grant
- 2011-08-02 CL CL2011001855A patent/CL2011001855A1/es unknown
- 2011-08-03 TN TN2011000381A patent/TN2011000381A1/fr unknown
- 2011-08-23 EC EC2011011285A patent/ECSP11011285A/es unknown
- 2011-08-30 CR CR20110464A patent/CR20110464A/es unknown
- 2011-09-01 ZA ZA2011/06412A patent/ZA201106412B/en unknown
-
2013
- 2013-04-22 US US13/867,951 patent/US20130310343A1/en not_active Abandoned
- 2013-08-30 ZA ZA2013/06536A patent/ZA201306536B/en unknown
-
2014
- 2014-01-10 PH PH12014500092A patent/PH12014500092A1/en unknown
-
2015
- 2015-12-04 US US14/959,412 patent/US9624250B2/en active Active
-
2017
- 2017-03-10 US US15/455,463 patent/US9988406B2/en active Active
-
2018
- 2018-05-03 US US15/970,486 patent/US10442829B2/en active Active
- 2018-05-03 US US15/970,492 patent/US10065947B1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33092B1 (fr) | Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one | |
LU92834I2 (fr) | Tédizolide, optionnellement sous la forme d'un ester, en particulier un phosphate ou un sel de celui-ci pharmaceutiquement acceptable | |
WO2006113615A3 (fr) | Agents antimicrobiens et utilisations de ceux-ci | |
MA37383A1 (fr) | Compose heterobicycliques comme inhibiteurs de la beta lactamase | |
CL2004000400A1 (es) | Compuestos derivados de piridina sustituida con 1,3-oxazol y con isoxazol, composicion farmaceutica, procedimiento de preparacion, utiles como agentes antibacteriano, activo contra la bacteria gram negativa. | |
WO2007023507A3 (fr) | Composition a activite antimicrobienne supportant des oxazolidinones ainsi que procedes de preparation associes | |
MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
MA32391B1 (fr) | Activateurs de la glucokinase | |
MA32104B1 (fr) | Dérivés d'oxime en tant qu'inhibiteurs de hsp90 | |
MA28484B1 (fr) | Culture de bacteries lactiques congelee sous forme de granules individuels. | |
TW200740800A (en) | Oxazolidinone compounds, and compositions and methods related thereto | |
TW200628474A (en) | Organic compounds | |
WO2003007870A3 (fr) | Derives d'oxazolidinone comme antimicrobiens | |
PE20060942A1 (es) | Derivados nonadepsipeptidos acilados ii como agentes bactericidas | |
MXPA05009688A (es) | Derivados de naftiridina como agentes antibacterianos. | |
MX2020013510A (es) | Composiciones para tratamiento, y metodos para fabricar y usar las mismas. | |
WO2010058423A3 (fr) | Nouveaux agents antimicrobiens | |
PE20060619A1 (es) | Derivados de oxazolidinona como antibacterianos | |
WO2017011730A3 (fr) | Dérivés de phénazine utilisés comme agents antimicrobiens | |
WO2006018682A3 (fr) | Derives d'oxazolidinone comme antimicrobiens | |
WO2007102061A3 (fr) | Promédicaments d'acide benzoquinolizine-2-carboxylique | |
PE20110161A1 (es) | 3-cianopirrolidinil-fenil-oxazolidinonas como agentes antibacterianos | |
WO2005035643A3 (fr) | Agent antiadherent inorganique | |
TH125050A (th) | รูปแบบที่เป็นผลึกของ R)-3-(4-(2-(2-เมทธิลเตตราซอล-5-อิล)ไพริดิน-5-อิล)-3-ฟลูออโรฟีนิล)-5-ไฮดรอกซีเมทธิลออกซาโซลิดิน-2-โอน ไดไฮโดรเจนฟอสเฟต (R)-3-(4-(2-(2-Methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate) | |
MX2021013992A (es) | I2-oxaespiro[5,5]undec-8-eno util en composiciones de fragancia. |